BeiGene
Clinical trials sponsored by BeiGene, explained in plain language.
A global biotechnology company developing and commercializing cancer treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New immunotherapy drug tislelizumab targets Hard-to-Treat cancers Results expected Nov 2026 (estimated)
- New study tracks targeted drug zanubrutinib in rare blood cancer Results expected Dec 2026 (estimated)
- New drug combo shows promise in advanced bladder cancer trial Results expected Jun 2027 (estimated)
-
New hope for rare blood cancer: zanubrutinib trial targets untreated patients
Disease control OngoingThis study tests the drug zanubrutinib (Brukinsa) in 18 Chinese adults who have Waldenström macroglobulinemia but have not yet received any treatment. The goal is to see how well the drug controls the disease and to check for side effects. Participants take zanubrutinib by mouth,…
Phase 4 • Sponsor: BeiGene • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug cocktail aims to stall colorectal cancer
Disease control OngoingThis study tests whether adding two experimental drugs (LBL-007 and tislelizumab) to standard maintenance therapy can help control advanced colorectal cancer that has not spread widely. About 113 adults with unresectable or metastatic colorectal cancer will receive either the new…
Phase 1/2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug combo shows promise in advanced bladder cancer trial
Disease control OngoingThis study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy helps people with advanced bladder cancer live longer. About 420 adults who have not had prior treatment for their advanced cancer will receive either tislelizumab plus chemo or a placebo…
Phase 3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cancer drug candidate BG-68501 enters first human trials
Disease control OngoingThis early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…
Phase 1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo takes on tough cancers: hope for advanced bladder, kidney, and melanoma patients
Disease control OngoingThis study is testing a new combination of two immunotherapy drugs (BGB-A445 and tislelizumab) in about 113 people with advanced bladder, kidney, or skin cancer that has spread. The goal is to see if the combo can shrink tumors and how safe it is. Participants must have already t…
Phase 1/2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for lung cancer: immunotherapy cocktail under study
Disease control OngoingThis phase 2 trial is testing whether combining the immunotherapy drug tislelizumab with other experimental drugs, with or without chemotherapy, can shrink tumors and control advanced non-small cell lung cancer. About 400 people who have not had prior treatment for metastatic dis…
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Immunotherapy combo shows promise against Early-Stage lung cancer
Disease control OngoingThis phase 3 study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy before and after surgery helps people with stage II or IIIA non-small cell lung cancer. About 453 participants will receive either tislelizumab plus chemo or a placebo plus chemo,…
Phase 3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug may delay return of ovarian cancer
Disease control OngoingThis study tests a drug called BGB-290 (Pamiparib) as a maintenance treatment for people with recurrent ovarian cancer whose tumors shrank or disappeared after platinum-based chemotherapy. The goal is to see if taking this drug daily can delay the cancer from coming back. The tri…
Phase 3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New pill could outshine chemo for common blood cancer
Disease control OngoingThis phase 3 trial tests whether the targeted drug zanubrutinib works better than the standard chemo combination of bendamustine plus rituximab for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 590 participants who cannot tole…
Phase 3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis phase 2 trial tests an oral drug called sonrotoclax (BGB-11417) in 100 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to prior treatments. The goal is to see if the drug can shrink or control the cancer. It is …
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for tough lymphoma: sonrotoclax trial underway
Disease control OngoingThis study tests a drug called sonrotoclax (BGB-11417) in 125 people with mantle cell lymphoma that has relapsed or not responded to prior treatments. The trial has two parts: first to find the safest dose, then to see how well it shrinks tumors. Participants take the drug by mou…
Phase 1/2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 26, 2026 14:39 UTC